SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract regarding HPN328 for the treatment of small cell lung cancer has been accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The meeting will be held from October 26-30, 2019 in Boston.

Details of the poster presentation are as follows:

Title: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer
Session Title: Therapeutic Agents: Biological
Session Date: Tuesday, October 29
Session Start Time: 12:30
Session End Time: 16:00
Location: Hall D, Hynes Convention Center
Abstract Number: C033

HPN328 is Harpoon’s fourth Tri-specific T cell Activating Construct (TriTAC™) candidate in development. HPN328 targets DLL3, a protein highly expressed in a majority of SCLC tumors with limited expression in normal tissues. This selective expression makes DLL3 an attractive drug target for T cell engagers. Harpoon is currently conducting IND-enabling studies and expects to initiate a Phase 1 clinical trial of HPN328 in 2020.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit


Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer

Westwicke ICR
Robert H. Uhl
Managing Director